Table 2.
Summaries of studies using functionalized MNPs for NIR-induced cancer therapy.
| Types of MNPs | Functionalizing Agents | Cancer Cells | Type of Study | NIR Light | Reference | |
|---|---|---|---|---|---|---|
| Wavelength (nm) | Intensity (W cm−2) |
|||||
| Spherical, hexagonal, and wire-like Fe3O4 | DSPE-PEG-COOH | Eca-10 | In vitro, in vivo | 655, 671, 808 | - | [104] |
| Iron oxide | Carboxymethyl chitosan, DOX | MCF-7 | In vitro, in vivo | 808 | 1.5 | [97] |
| Regular and sphere shape Fe3O4 | NHS-PEG-Mal, folic-acid, DOX | HepG2 | In vitro | 808 | 2 | [112] |
| Iron oxide | CuS, DOX | MCF-7 | In vitro, in vivo | 980 | 2 | [113] |
| Citric-acid-capped iron-oxide | CET, TSLs, DOX | SKBR-3, MCF-7 | In vitro, in vivo | 808 | 2 | [114] |
| Fe3O4-core Au shell | PPY | HeLa | In vitro | 808 | 2 | [121] |
| Individual and clustered Fe3O4 | - | A549 | In vitro, in vivo | 808 | 5 | [95] |
| CuFeSe2 nanocrystals | poly(methacrylic acid) | 4T1 | In vitro, in vivo | 808 | 1 | [96] |
| Magnetite/maghemite nanospheres and nanoflowers | - | SKOV-3, PC3 | In vitro | 1064 | 0.3, 1 | [101] |
| Oleate-Fe3O4 and pristine Fe3O4 | Peptide | 4T1 | In vitro, in vivo | 808 | 2 | [105] |
| Clustered Fe3O4 | Calcium oxalate dehydrate | HeLa | In vitro | 808, 1064 | 0.38 | [107] |
| Oleic-acid capped Fe3O4 | 10-Hydroxy camptothecin, NIPAm, MAA, mPEGMA | MCF-7, 4T1 | In vitro, in vivo | 808 | 3 | [110] |
| Fe3O4 | Core–shell (Fe2O3@Au) | CT26 | In vitro, in vivo | 808 | 1.4 | [115] |
| Clustered Fe3O4 | Au nanopopcorns, PEG | KB-3-1, SK-BR-3 | In vitro | 808 | 0.55 | [116] |
| Fe3O3@Au (core–shell) | - | B16-F10 | In vivo | 808 | 2.5 | [117] |
| Fe3O4@Au (core–shell) | - | KB | In vitro | 808 | 6.3 | [118] |
| Fe3O4@Au (core–shell) | Poly-L-lysine | BT-474, MDA-MB-231 | In vitro | 808 | 1 | [120] |
| Fe3O4@Au nanords | HA, MS, DOX | HCT 116, HEK 293 | In vitro, in vivo | 980 | 3 | [127] |
| Fe3O4@SiO2 (core–shell) | PEI-FPBA, ICG, TMZ | U87 MG | In vitro | 808 | 1 | [128] |